

PHARMACY POLICY STATEMENT

DATE	ACTION/DESCRIPTION
1/26/2024	New policy for Wainua created.

References:

1. Wainua [prescribing information]. Wilmington, DE AstraZeneca Pharmaceuticals LP; 2023.
2. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. *Orphanet J Rare Dis.* 2013;8:31
3. National Institutes of Health (NIH). Transthyretin amyloidosis. Available at: <https://ghr.nlm.nih.gov/condition/transthyretin-amyloidosis>.
4. Amyloid transthyretin (ATTR) Amyloidosis: Signs, symptoms, and diagnostic workup. 2018 Akcea Therapeutics, Inc. Available at: <https://www.hattrguide.com/wp-content/uploads/2018/04/Diagnostic-Card.pdf>
5. BioNews Services, LLC. Stages of familial amyloid polyneuropathy. Available at: <https://fapnewstoday.com/stages-of-familial-amyloid-polyneuropathy/>
6. Coelho T, Marques Jr W, Dasgupta NR, et al. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. *JAMA*(n)18(s)-37(t)47(h)18(1.17 Tm(h)18()) TJETQq0.00000912 0 612 7 5WTQ8)18(: 0 1 249.13 5